- Home
- STTK vs ATLO Comparison
STTK vs ATLO Comparison
Compare STTK & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ATLO
- Stock Information
- Founded
- STTK 2016
- ATLO 1903
- Country
- STTK United States
- ATLO United States
- Employees
- STTK N/A
- ATLO N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ATLO Major Banks
- Sector
- STTK Health Care
- ATLO Finance
- Exchange
- STTK Nasdaq
- ATLO Nasdaq
- Market Cap
- STTK 37.6M
- ATLO 158.4M
- IPO Year
- STTK 2020
- ATLO N/A
- Fundamental
- Price
- STTK $0.83
- ATLO $18.10
- Analyst Decision
- STTK Hold
- ATLO
- Analyst Count
- STTK 4
- ATLO 0
- Target Price
- STTK $3.00
- ATLO N/A
- AVG Volume (30 Days)
- STTK 423.3K
- ATLO 17.8K
- Earning Date
- STTK 07-31-2025
- ATLO 08-08-2025
- Dividend Yield
- STTK N/A
- ATLO 4.35%
- EPS Growth
- STTK N/A
- ATLO 14.69
- EPS
- STTK N/A
- ATLO 1.27
- Revenue
- STTK $4,606,000.00
- ATLO $55,041,000.00
- Revenue This Year
- STTK N/A
- ATLO N/A
- Revenue Next Year
- STTK N/A
- ATLO N/A
- P/E Ratio
- STTK N/A
- ATLO $14.54
- Revenue Growth
- STTK 69.65
- ATLO 6.77
- 52 Week Low
- STTK $0.69
- ATLO $15.69
- 52 Week High
- STTK $4.99
- ATLO $22.03
- Technical
- Relative Strength Index (RSI)
- STTK 38.86
- ATLO 59.86
- Support Level
- STTK $0.75
- ATLO $18.16
- Resistance Level
- STTK $0.85
- ATLO $18.68
- Average True Range (ATR)
- STTK 0.09
- ATLO 0.34
- MACD
- STTK -0.01
- ATLO 0.08
- Stochastic Oscillator
- STTK 9.59
- ATLO 83.13
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ATLO Ames National Corporation
Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.